Hemophilia A, also known as classical hemophilia, is a genetic bleeding disorder caused by insufficient or defective clotting factor VIII, a protein essential for blood coagulation. Individuals with hemophilia A experience prolonged bleeding or spontaneous bleeding episodes, particularly in joints and muscles, which can lead to pain and joint damage over time. Management includes regular infusions of factor VIII concentrates to prevent or treat bleeding episodes, and advances in treatment have significantly improved quality of life and life expectancy for those affected.
Patients are the experts in their condition and advocacy groups provide a platform for patient voices. Working directly with these communities is the key to pushing research forward in an inclusive way.
Hemophilia A (pronounced as “hee-muh-FEE-lee-uh”) is a rare bleeding disorder that affects thousands of individuals worldwide. Hemophilia A is a complex bleeding disorder that impacts individuals and their families. By understanding this rare disease and its impact on patient lives, we can raise awareness and support affected individuals to manage the challenges associated with this condition.
Read more...
We’ve committed to having 500,000 conversations in the next three years, to equip ourselves and our Pharma partners with the insights needed to increase predictability.
Read more...
The ever-growing investment in advocacy doesn’t appear to be slowing down, and research is certainly seeing the benefits. Which at the end of the day, means better patient care and more options for patients.
Read more...
We’re ready to keep forming links between our Advocacy friends and Pharma partners, so these fruitful relationships continue to evolve beyond the study-to-study view.
Read more...